What’s Beyond Poolability: Exchangability

Slides:



Advertisements
Similar presentations
Roseann White Clin/Reg Felllow Abbott Vascular – Cardiac Therapies
Advertisements

Role of the Statistician and the Bioinformatics Scientist in Cancer Clinical Trials Larry Rubinstein, PhD Biometric Research Branch, NCI International.
Appreciating the unpredictable: A case study of questions Steven E. Wallis, Ph.D. (HOD class of 2006) Fellow, Institute for Social Innovation (ISI) Director,
Customer Success Is Our Mission 1 Ed Franklin Raytheon Company Evaluation Team March 23, 2005 The RCET: What is it? and What have we seen?
The Risk and Extent of Neurological Events Are Equivalent for High-Risk Patients Treated With Transcatheter or Surgical Aortic Valve Replacement Thomas.
Template Title Speaker Name Subtitle. Disclosure Statement of Financial Interest Grant/Research Support Consulting Fees/Honoraria Major Stock Shareholder/Equity.
Cost-Effectiveness of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention in Patients with Stable Coronary Disease: Results from the FAME.
Title of Presentation Presenter Name, Designation Presenter 2 Name, Designation Presenter 3 Name, Designation.
CIT 2016 Template Title 40 pt Bold Arial David Liu, MD Subtitle 34 pt Arial Bold Italics.
1 Data Quality Report Quality Assurance Report Live Data Download Site Datasets (SAS) Research Datasets Customized Cohort Reports Outcome Analytics Patient.
Strategies to Improve Inadequate Guide Catheter Support John S Douglas Jr MD S Tanveer Rab MD Emory University School of Medicine Atlanta Georgia Sunday.
PRAGMATIC Study Designs: Elderly Cancer Trials
MKT 421 Week 1 DQ 1 What is the definition of marketing? What are the benefits and drawbacks of incorporating marketing into the sales function of an organization?
MGT 311 Week 1 DQ 2 What type of assessments and evaluations might you use to determine the characteristics of your employees? Does the type of tool used.
FIN 200 WEEK 7 CHECKPOINT SHORT TERM FINANCING CheckPoint: Short-Term Financing · Write a 200- to 300-word paper listing the different sources of short-term.
FIN 486 Week 1 DQ 1 What are a chief financial officer’s (CFO) two roles? Use real-world examples to explain why these roles are important to a company’s.
ACC 290 Week 1 DQ 1 What are the four basic financial statements? What is the primary purpose of each of the four basic financial statements? In your opinion,
Martin B. Leon, MD Key Messages Tryton Pivotal: Randomized Trial and
Study Design: Making research pretty Adam P. Sima, PhD July 13, 2016
Leveraging Bayesian Methodology to Increase the Trial Efficiency
Disclosure Statement of Financial Interest
Essentials of Quality Control
Issues and Current Situations in the Development of Endovascular Treatment Devices for Pediatric Cardiology in the US – US Industry Dan Gutfinger, MD,
BUS 308 mentor innovative education/bus308mentor.com
5 Different Observational Datasets: Pros & Cons
LAAO with Watchman Device Post-Procedure Best Practices
FDA Division of Cardiovascular Devices
Updates From NOTION: The First All-Comer TAVR Trial
Are we ready for expanding TAVI indications to moderate and low risk
Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S
Use of Prior Information (Clinical, Pre-clinical and Models) to Improve Efficiency and the Efficacy Estimates Roseann M. White, MA Director of Clinical.
FDA’s IDE Decisions and Communications
Early Feasibility Studies Investigator Perspective
Medtronic Cardiovascular,
Surgical Mitral Valve Repair: What is the Gold Standard?
Harmonized Assessment by Randomized Multicenter Study of OrbusNEich’s COMBO StEnt Japan-USA HARMONEE: Primary Report of A Randomized Trial of a Bioabsorbable.
Disclosure Statement of Financial Interest
The Tryton Bifurcation Trial:
Lessons Learned Through HBD: The Industry’s View
FAVOR II Europe-Japan FAVOR II E-J
OCT-Guided PCI What needs to be done to establish criteria?
The Landscape of NHLBI Investment in Plaque Vulnerability Research
Preliminary results of the Elutax SV Italian registry
Erica Takai, PhD for Andrew Farb, M.D.
TRANSCATHETER MITRAL VALVE IMPLANTATION FOR SEVERE MITRAL REGURGITATION: THE TENDYNE GLOBAL FEASIBILITY TRIAL 1 YEAR OUTCOMES David WM Muller, MBBS,
PM 571Competitive Success/tutorialrank.com
Late Follow-Up from the PARTNER Aortic Valve-in-Valve Registry
Consulting Services.
Boston University Executive MBA Program
Speaker Disclosure slides for presentations
CIT 2018 Template Title 40 pt Bold Arial
Significant (greater than $10K)
CIT 2018 Template Title 40 pt Bold Arial
CIT 2017 Template Title 40 pt Bold Arial
CIT 2018 Template Title 40 pt Bold Arial
CIT 2017 Template Title 40 pt Bold Arial
Focus on Quality Webinar July 2018 Indiana Quality Improvement Network
CIT 2017 Template Title 40 pt Bold Arial
CIT 2017 Template Title 40 pt Bold Arial
Advanced Statistical Methods for Translational Research
Disclosures Relevant financial relationships in the past twelve months by presenter or spouse/partner.    Employment: Company Name(s) Speakers Bureau:
Title of Talk Speaker name.
Improving the Standards of Reporting of Clinical Trial Data
Title 40pt Trebuchet MS Bold
Disclosure Statement of Financial Interest
Disclosure Statement of Financial Interest
List disclosure information here.
Financial Disclosure Financial Interest / Affiliation
CIT 2018 Template Title 40 pt Bold Arial
Transcatheter versus medical treatment of symptomatic severe tricuspid regurgitation: a propensity score matched analysis Maurizio Taramasso MD, PhD from.
Presentation transcript:

What’s Beyond Poolability: Exchangability Roseann White, MA Director Pragmatic Clinical Trial Statistics Duke Clinical Research Institute

Acknowledgements Dawn Bardot, VP Tecnologies, MDIC Dan Schwartz, PM, MDIC Tarek Haddad, Ph.D., Director, MDT

Disclosure Statement of Financial Interest Within the past 12 months, I or my spouse/partner have had a financial interest/arrangement or affiliation with the organization(s) listed below. Affiliation/Financial Relationship Company Employee Consulting Fees/Honoraria Other Financial Benefit Duke Clinical Research Institute Claret Abbott, Abbvie

“Um,” my son muttered sheepishly, “I’d rather have the real ones.” My 8th-grade–bound son has long coveted classic Converse low-tops. Last week, we found a pair of lookalikes on sale for $15. “Um,” my son muttered sheepishly, “I’d rather have the real ones.” “.. they look … exactly the same.” “Not exactly,” he explained. “These” [referring to the Converse low-tops], “have a label.” From the Santa Barbara Independent newspaper, July 21, 2011 by Starshine Roshell

Exchangability: outcomes from persons from two sources can be explained by deterministic characteristics and random error UNC and Duke University Basketball Teams are exchangeable 2015 UNC won 33 out of 40 games, i.e. 85% 2015 Duke University won 25 out of 36 games, i.e. 70%

What do we want to look at to assess exchangeability Trial Design: inclusion/exclusion criteria, primary endpoint, …….. Geography Device Definitions of the outcomes, key baseline characteristics,……. Quality of the Data: monitoring level , adjudication, ……. Follow-up: same schedule of follow-up visits, same kind of follow-up visits, ……. Your statistician can assist but the clinician/clinical trial scientist is the final judge of exchangability

Completely Exchangeable  Completely Separate

Comparing Historical Data to your Current Data 100% Completely Exchangeable (poolable): any differences between in outcomes between the can be adjusted for by deterministic characteristics Partial/Conditional: average outcomes for persons from historical and current data, after adjusting for deterministic characteristics, arise from a common distribution Completely Separate: we ignore the historical information except in how it might help us understand designing a study from “scratch” 0%

Why do we want to know exchangability? Historical Historical Historical Current Current Current

To determine the discount function one needs to balance: Creating the Discount Function: Collaborative Effort between Statistician and Clinical Scientist To determine the discount function one needs to balance: Type I error: False Hope Type II error: Missed opportunity Bias: Smallest clinical meaningful shift in outcomes

“Past is prologue” William Shakepeare (a literary Bayesian)